Pluristem Issues 2.5M Shares in Exchange for 1.011M Shares of CHA

Pluristem Therapeutics

today announced that pursuant to the previously announced exclusive out-license and strategic partnership agreement between Pluristem Ltd. and South Korea-based CHA Bio&Diostech

, the details of which were announced on June 26, 2013, Pluristem and CHA entered into investment agreements pursuant to which Pluristem has issued to CHA 2,500,000 shares of its common stock in consideration for the issuance to Pluristem of 1,011,504 shares of CHA. This reflects a total consideration of $10.4 million, at a price of $4.16 per Pluristem common share, a premium of 26% over the closing price on December 16, 2013. The shares are subject to a lock up period of one year. The previously announced agreement with CHA encompasses the use of Pluristem's PLX-PAD cells in the treatment of two subsets of Peripheral Artery Disease (PAD) in South Korea: Intermittent Claudication (IC) and Critical Limb Ischemia (CLI). Zami Aberman, Pluristem's Chairman and CEO stated, "We are excited to finalize and move forward with this strategic